Search Results for "Hydromorphone"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Hydromorphone. Results 1 to 3 of 3 total matches.
Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
-10, and 11-
13) with intramuscular hydromorphone 18 mg
and 6 mg and placebo. In the 12 days after ...
The FDA has approved a subcutaneously injected,
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Brixadi – Braeburn)
for once-weekly or once-monthly treatment of
moderate to severe opioid use disorder. Brixadi is
the second subcutaneously injected buprenorphine
formulation to be approved in the US; Sublocade,
which is administered once monthly, was the first.
Buprenorphine is also available for treatment of
opioid use disorder in sublingual formulations with
and without the opioid antagonist...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):133-5 doi:10.58347/tml.2023.1683c | Show Introduction Hide Introduction
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
opioid that is partly metabolized by CYP2D6
to hydromorphone. Immediate-release formulations ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
in a fixed-dose combination with acetaminophen 31.20
31.20
Hydromorphone – generic
Dilaudid (Rhodes ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics